

1 *Supplementary Material*

2 **Investigation of cytotoxicity and cell uptake of**
3 **cationic beta-cyclodextrins as valid tools in nasal**
4 **delivery**

5 **Giovanna Rassu** ^{1,§}, **Silvia Fancello** ^{2,§}, **Marta Roldo** ³, **Milo Malanga** ⁴, **Lajos Szente** ⁴, **Rossana**
6 **Migheli** ^{2,*}, **Elisabetta Gavini** ^{1,*} and **Paolo Giunchedi** ¹

7 ¹ Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy.

8 grassu@uniss.it (GR); eligav@uniss.it (EG); pgiunc@uniss.it (PG)

9 ² Department of Medical, Surgical and Experimental Sciences, University of Sassari, viale San Pietro 43/b,
10 07100 Sassari, Italy. sfancello@uniss.it (SF); rmigheli@uniss.it (RM)

11 ³ School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.

12 marta.roldo@port.ac.uk

13 ⁴ CycloLab Ltd., H-1097 Budapest, Illatos út 7, Hungary. malanga@cyclolab.hu (MM); szente@cyclolab.hu
14 (LS)

15

16 § authors contributed equally.

17

18 * Correspondence: eligav@uniss.it; Tel.: +39 079 228 752 (EG); rmigheli@uniss.it; Tel.: +39 079 228 528 (RM)

19


20

21

Table 1S. Description of beta-cyclodextrin monomers and polymers studied in this work

Not Fluorescent						Analogue fluorescent cyclodextrin						
Cyclodextrin	Code	DS ¹	MW ²	CLR ³	CD ⁴	Description	Cyclodextrin	Code	DS ¹	MW ²	CLR ³	CD ⁴
(2-Hydroxy-3-N,N,N-trimethylamino) propyl-beta-cyclodextrin chloride	QA	3	1589.8	-	3	cationic monomer; purity > 99%	Quaternary ammonium-6-deoxy- 6-[(5/6)-rhodaminyl thioureido]-(2-Hydroxy-3-N,N,N-trimethylamino)-beta-cyclodextrin	RBIT C-QA	4.5 (QA) 1 (RBITC)	1939.8 6	-	3.5
Quaternary-ammonium-beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin	QAPS	2.2	40,000	~11	2.2	cationic polymer; CD content: 50-70%	Quaternary-ammonium-rhodamine labeled beta-cyclodextrin soluble polymer crosslinked with epichlorohydrin	RBIT C-QA PS	2.2 (QA) 0.05 (RBITC)	40,000	~11	2.2
Heptakis (6-deoxy-6-amino)-beta-cyclodextrin heptahydrochloride	HA	-	1383.3	-	7	cationic monomer; purity > 98%						
Soluble amino-beta-cyclodextrin polymer crosslinked with epichlorohydrin	HAPS	1	25,000	~10	1	cationic polymer; CD content: 70%						
(2-Hydroxypropyl)- beta-cyclodextrin	HP	4.5	1400	-	-	control monomer	6-deoxy-6-[(5/6)-rhodaminylthioureido]- hydroxypropyl-beta-cyclodextrin	RBIT C-HP	4.7 (HP) 0.5 (RBITC)	1675.0 7		1*
Soluble β -cyclodextrin polymer crosslinked with epichlorohydrin	PS	-	92,000	~11	-	control polymer; CD content: 70%	Rhodamine labeled BCD soluble polymer crosslinked with epichlorohydrin	RBIT C-PS	0.05 (RBITC)	100,00 0	~11	-


¹DS: Average Degree of Substitution; ²MW: Average Molecular Weight (g/mol); ³CLR: Cross-Linking Ratio (mol epichlorohydrin/mol CD); ⁴CD: Cationic Density (cationic groups per cyclodextrin unit). * anionic group per cyclodextrin unit



25

26 **Figure 1S.** Cartoon representations for beta-cyclodextrin monomers: a) HP; b) HA; c) QA; d) RBITC-HP; e)
 27 RBITC-QA.

28



29

30 **Figure 2S.** Cartoon representations for beta-cyclodextrin polymers: : a) PS; b) HAPS; c) QAPS; d)
 31 RBITC-PS; e) RBITC-QAPS.

32





Figure 3S. Effect of different concentrations (0.5 - 1 - 2.5 - 5 - 10 μM) of HP, QA and QAPS on PC12 cell viability at increasing times of exposure (15, 30, 60 min and 24h). *p<0.05 vs Control.

33
34
35
36

37




38

39

40


Figure 4S. Effect of different concentrations (0.5 - 1 - 2.5 - 5 - 10 μM) of HA, HAPS and PS on PC12 cell viability at increasing times of exposure (15, 30, 60 min and 24h). *p < 0.05 vs Control.

41



42
43
44

Figure 5S. Effect of different concentrations (0.5 - 1 - 2.5 - 5 - 10 μM) of HP, QA and QAPS on CACO-2 cell viability at increasing times of exposure (15, 30, 60 min and 24h). *p<0.05 vs Control.



45
46
47

Figure 6S. Effect of different concentrations (0.5 - 1 - 2.5 - 5 - 10 μM) of HA, HAPS and PS on CACO-2 cell viability at increasing times of exposure (15, 30, 60 min and 24h). *p < 0.05 vs Control.